Medical Oncologist, Professor, Department of Medical Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB
Dr. North completed his medical training at the University of Ottawa in 1994. He then moved to Edmonton and completed Internal Medicine and Medical Oncology training at the University of Alberta. His interest in teaching led him to pursue a Masters in Health Professions Education from the University of Illinois at Chicago which he obtained in 2004.
Dr. North is presently the Director of Medical Oncology at the Cross Cancer Institute and a Professor in the Department of Oncology, Faculty of Medicine and Dentistry at the University of Alberta. His clinical practice is limited to genitourinary oncology only.
He is an active clinician, teacher and researcher. He participates actively in clinical trials and has over 50 peer reviewed publications.
Parimi S, Eliasziw M, North SA, Trudeau M, Winquist E, Chi KN, Ruether D, Cheng T, Eigl BJ. Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Invest New Drugs. 2016 Dec;34(6):771-776. PMID: 27565809
Chi KN, Spratlin J, Kollmannsberger C, North SA, Pankras C, Gonzalez M, Bernard A, Stieltjes H, Peng L, Jiao J, Acharya M, Kheoh T, Griffin TW, Yu MK, Chien C, Tran NP. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol. 2015 Dec;55(12):1406-14. PMID: 26096139
Vicente C, Loblaw A, North SA, Kassouf W, Naidoo S, Husein F, Nakhaipour HR. Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt). Value Health. 2015 Nov;18(7):A474. PMID: 26532661
Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct;68(4):570-7. PMID: 25985882
Chi K, Hotte S.J, Joshua A.M, North SA, Wyatt A.W, Collins L.L, Saad F. Treatment of mCRPC in the AR axis-targeted therapy resistant state. Ann Oncol. 2015 Oct;26(10):2044-56.PMID: 26101426
Norris M.K, Bell G.J, North SA, Courneya K.S. Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial. Prostate Cancer and Prostatic Disease. 2015 Sep;18(3):281-7. PMID: 26078203
Eigl B.J, North SA, Winquist E, Finch D, Wood L, Sridhar S.S, Powers J, Good J, Sharma M, Squire J.A, Bazov J, Jamaspishvili T, Cox M.E, Bradbury P.A, Eisenhauer E.A, Chi K.N. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinica trials group study IND195. Investigational New Drugs, August 2015, Volume 33, Issue 4, pp 969 – 976. PMID: 25983041
Saad F, Chi KM, Finelli A, Hotte SJ, Izawa J, Kapoor A, Kassouf W, Loblaw A, North SA, Rendon R, So A, Usmani N, Vigneault E, Fleshner NE. The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. PMID: 26085865
Trinh L, Plotnikoff RC, Rhodes RE, North S, Courneya KS. Feasibility and preliminary efficacy of adding behavioral counseling to supervised physical activity in kidney cancer survivors. Cancer Nursing, Vol. 00, No. 0, 2013, pp 1015.
Seah, J-A, Sridhar S, Wood L, Blais N, North S, Rahim Y, Ruether D, Black P, Zlotta A. Consensus Statement: Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Canadian Urological Association Journal, Vol 7, No 9-10 (2013).
Organ M, Wilke D, Wood L, Cheng T, North S, Rendon RA. Predictors of testosterone recovery in patients with castrate resistant prostate cancer who have stopped hormonal therapy. NS-AUA, October 2013. CUAJ 7(9-10):P12 (pg 366).
Pervez N, El-Gehani F, Joseph K, Dechaphunkul A, Kamal M, Pertschy D, Venner P, Ghosh S, North S. Genitourinary small-cell carcinoma: a single-institution experience. Curr Oncol, Vol. 20, Number 5, October 2013, pp. 248-264.
North S, Basappa N, Bjarnason G, Blais N, Canil C, Heng D, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update. Can Urol Assoc J 2013;7(7-8):238-43.
Saad F, Hotte S, Catton C, Drachenberg D, Finelli A, Fleshner N, Gleave M, Kapoor A, Kassouf W, Lobloaw A, North S, Usmani N, Chi K. CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J 2013:7(7-8):213-7.
Kroeger N, Choueiri T, Lee J-L, Bjarnason G, Knox J, MacKenzie M, Wood L, Srinivas S, Vaishampayan U, Rha S-Y, Pal S, Yuasa T, Donskov F, Agarwal N, Tan M-H, Bamias A, Kollmannsberger C, North S, Rini B, Heng D. Survival Outcome and Treatment Response of Patines with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European Urology (epub ahead of print July 30, 2013).
Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol, 2013, Jul; 24(7):1802-07.
Trinh L, Plotnikoff R, Rhodes R, North S, Courneya K. Associations between sitting time and quality of life in a population-based sample of kidney cancer survivors. Mental Health and Physical Activity, 2013; 6(1): 16-23.
McGowan EL, North S, Courneya KS. Randomized controlled trial of a behavior change intervention to increase physical activity and quality of life in prostate cancer survivors. Ann Behav Med, doi 10.1007/s12160-013-9519-1, published online June 20, 2013
Moretto P, Wood L, Emmenegger U, Blais N, Mukherjee SD, Winquist E, Belanger EC, MacRae R, Balogh A, Cagiannos I, Kassouf W, Black P, Czaykowski P, Gingerich J, North S, Ernst S, Richter S, Sridhar S, Reaume MN, Soulieres D, Eisen A, Canil CM. Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J, 2013; 7:E44-E56.
Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan M-H, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY for the Inernational mRCC Database Consortium. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targ Oncol DOI 10.1007/s11523-012-0252-7 Epub January 9, 2013.
Logothetis CJ, Basch EM, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of Abiraterone acetate on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer post-docetaxel: results of the COU-AA-301 study. Accepted for publication. Lancet Oncol, 13(12); 1210-7, December 3, 2012.
Sternberg CN, Molina A, North S, Mainwaring P, Hao Y, Rothman M, Gagnon D, Kheoh T, Haqq C, de Bono JS, Scher HI. Effect of Abiraterone acetate on fatigue in patients with metastatic castration resistant prostate cancer post-docetaxel. Accepted for publication. Ann Oncol. 2012 Oct.
Trinh L, Plotnikoff RC, Rhodes RE, North S, Courneya KS (in press). Associations between sitting time and quality of life in a population-based sample of kidney cancer survivors. Ment Health Phys Act, doi: 10.1016/j.mhpa.2012.09.001, October 2012.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; for the COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 20;13(10):983-992, October 2012. Epub: DOI: 10.1016/S1470-2045(12)70379-0, September 18, 2012.
Trinh L, Plotnikoff RC, Rhodes RE, Scott N, Courneya KS: Correlates of physical activity in population-based sample of kidney cancer survivors: An application of the theory of planned behavior. Int J Behav Nutr Phys Act 2012, 9:96. doi:10.1186/1479-5868-9-96, August 2012.
Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN,Tan M-H, Rha S-Y, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DYC, Choueiri TK. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol, 13(9); 927-35, September 3, 2012.
Organ M, Wood L, Wilke D, Skedgel C, Cheng T, North S, Thompson K, Winch S, Rendon R. Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. Am J Clin Oncol (epub ahead of print), August 2, 2012.
Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J, Canil C, Heng D, Reaume N, Tanguay S, Atkins M, Bjarnason G, Dancey J, Evans M, Fleshner N, Haider M, Kapoor A, Uzzo R, Maskens D, Soulieres D, Yousef G, Basappa N, Bendali N, Black P, Blais N, Cagiannos I, Care M, Chow R, Chung H, Czaykowski P, Derosa D, Durrant K, Ellard S, Farquharson G, Filion-Brulotte C, Gingerich J, Godbout L, Grant R, Hamilton W, Kassouf W, Kurban G, Lane K, Lattouf J, Lau D, Leveridge M, McCarthy J, Moore R, North S, O’brien P, Pituskin E, Racine P, Rendon R, So A, Sridhar S, Stubbs K, Su Z, Taylor L, Udall T, Venner P, Vogel W, Yap S, Yau P, Cooper M, Giroux N, Miron D, Mosher D, Ross K, Willacy J. Management of Kidney Cancer: Canadian Kidney Cancer Forum Consensus Update 2011. Can Urol Assoc J, 6(1):16-22. doi: 10.5489/cuaj.1127. February 3, 2012.
Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol, (Epub ahead of print), November 5, 2011.
Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Yong JH, Saad F. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Curr Oncol, Vol 18(2):S11-9, October 2011.
Trinh L, Plotnikoff RC, Rhodes RE, North S, Courneya K. Physical activity preferences in a population-based sample of kidney cancer survivors. Supportive Care in Cancer, (Epub ahead of print), September 24, 2011.
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; for the Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06c. Clin Cancer Res, Vol 17(17):5765-5773, September 1, 2011.
Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, Mukherjee S, Chi KN. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naïve castration resistant prostate cancer. Invest New Drugs (Epub ahead of print), July 23, 2011.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JS, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, Vol 364(21):1995-2005, May 26, 2011.
Trinh L, Plotnikoff RC, Rhodes RE, North S, Courneya K. Associations between physical activity and quality of life in a population-based sample of kidney cancer survivors. Cancer Epidemiol Biomarkers, Vol 20(5):859-68, May 2011.
Choueiri TK, Xie W, Kollmannsberger C, North S, Knox J, Lampard JG, McDermott DF, Rini BI, Heng DYC. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urology, Vol 185: 60-6, January 2011.
Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Current Oncology, Vol 18(1):e25, January 2011.
De Souza PL, North S, Bolger GB, Spiridonidis H, Lim R, Khoo KS, Phillips J, Fujimori M. A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. Asia-Pacific J Clin Oncol, Vol 6(4):292-7, December 6, 2010.
Chi KN, Hotte SJ, Yu YE, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol, Vol. 28(27):4247-54, Sept 2010.
Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY. Clinical outcomes in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology, Vol. 76(2): 430-4, August 2010.
Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O’Mally M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J, Vol. 4(2): e19-38, Apr 2010.
Hanninen M, Venner P, North S. A rapid PSA halflife following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J, Vol. 3(5): 369-74, Oct 2009.
Warren, M, Venner, PM, North, S, Cheng, T, Venner, C, Ghosh, Venner, AA, Finch, D. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta, and the role of nephrectomy prior to treatment. Can Urol Assoc J, Vol. 3(4): 281-289, Aug 2009.
Heng DYC, Xie W, Regan MM, Warren M, Golshayan AR, Sahi C, Eigl, BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh, WK, Atkins MB, Bukowksi RM, Rini BI, Choueire TK. Prognostic factors of overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol, Vol. 27(34): 5794-9, Dec 1, 2009.